Ser163
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser163  -  NFAT4 (human)

Site Information
SYRESSLsPsPASSI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448857

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , electrophoretic mobility shift ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 ) , phosphopeptide mapping ( 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
JNK2 (human) ( 3 )
Kinases, in vitro:
JNK2 (human) ( 3 )

Downstream Regulation
Effects of modification on NFAT4:
intracellular localization ( 3 )
Effects of modification on biological processes:
transcription, inhibited ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

3

Chow CW, et al. (1997) Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278, 1638-41
9374467   Curated Info